SPARC — AI Stock Dissection

AI Stock Dissection

Fetching the live quote…Computing price structure…Running the AI dissection…Writing the executive briefing…Scoring risks & catalysts…

Sensai

Reading the tape…Pulling live market data…Setting the scene…

AI Stock Dissection

SPARCLive

SPARC

Mr. Anilkumar Raghavan · Mumbai, India · 279 employees

₹213.17

▲+2.01%

SPARC is experiencing extraordinary financial performance with explosive revenue growth and exceptional profitability, trading at a significant discount to its 52-week high.

Exchange

NSI

Currency

INR

Day range

₹209.76 – ₹216.88

52-week range

₹108.00 – ₹289.00

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

AI investment rating

AI analysis

Buy

75% confidence

Current price of 213.17 INR appears significantly undervalued given the exceptional profitability metrics and trading well below the 52-week high of 289, suggesting substantial upside potential.

Position in 52-week range

Live

52w low58%52w high

26.2% below the 1-year high · trend up

Fundamentals

Live

Market cap69.18B

Hedge-fund memo

Executive AI briefing

AI analysis

Today

Positive momentum with 2.01% gain on high volume, indicating renewed investor interest.

This week

Continued upward trajectory as the stock consolidates above 200 INR level.

This month

Strong recovery from lower levels, though still well below 52-week highs.

Bull thesis

Exceptional profit margins of 82.65% indicate superior pricing power and operational efficiency
Explosive YoY revenue growth of 6,716.80% suggests successful market expansion or product launch

Bear thesis

Debt/Equity ratio of 41.78% indicates elevated financial leverage
Low institutional ownership of 1.79% may limit institutional support

Hidden risks

News & sentiment

What the press is saying

24 headlines · live

Neutral

24 headlines · 20 outlets · 7d

Tone · daily average

07-2407-29

+40
Sparc Technologies (ASX:SPN) Advances Green Hydrogen and Graphene Technology Portfolio as Commercialisation Milestones Remain Key Focus

Smart money

Who owns it

Live

Ownership split

Insiders / promoters75.12%

Institutions (FII/DII/MF)1.79%

Public & others23.089999999999996%

Top institutional holders

Not listed

Named holders aren't published for this listing (common for Indian stocks). The split at left is live.

Financial health

The numbers

Live

Profitability

Return on equity276.89%
Return on assets79.74%
Profit margin82.65%
Operating margin96.11%
Gross margin98.41%

Growth

Revenue (TTM)18.79B
Revenue growth6,716.80%
Earnings growth—

Balance sheet

Debt / equity41.78%

07b

Financial statements

Multi-year trend

Live

Line item

2014201820242025

Revenue

₹1.8B

₹83.2Cr

₹1.1B

₹0

Gross profit

₹0

Earnings intelligence

Beat history

Unavailable

Earnings history unavailable for this symbol.

Competitive landscape

Versus peers

Live

Company	Market cap	P/E	ROE	Op. margin	Rev. growth
SPARCSPARC	69.18B	4.45	276.89%	96.11%	6,716.80%
STARStrides Pharma Science Limited	97.70B	17.58	20.03%	8.56%	11.20%
WOCKPHARMAWockhardt Limited	309.39B	146.12	4.00%

Technical intelligence

Price structure

Live

SPARCdaily · candles

Hover the chart for that day's open / high / low / close, volume and RSI.

Volume

RSI (14) · 70 overbought / 30 oversold

MACD (12,26,9) · MACD vs signal

Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.

Risk intelligence

What could go wrong

AI analysis

Regulatory changes affecting generic drug pricing

P: MediumImpact: High

Mitigation: Diversification of product portfolio and expansion into specialty segments

Increased competition eroding profit margins

P: MediumImpact: High

Mitigation: Continued investment in R&D and operational efficiency

Business intelligence

Moat · supply chain · M&A

AI analysis

Competitive moat

Exceptional profit margins and pricing power in generic drug market with demonstrated ability to achieve extraordinary growth rates.

Supply chain

Upstream (inputs / suppliers)

Active pharmaceutical ingredients (APIs)Raw material suppliers

↓

Downstream (customers / markets)

Pharmaceutical distributorsRetail pharmaciesHospital networks

M&A / strategic moves

No notable recent acquisitions, divestitures, JVs or strategic moves disclosed in the provided data

Catalyst calendar

What to watch next

AI analysis

Next 3-6 monthsHigh impact
Potential product pipeline expansion
Next 6-12 monthsMedium impact
Possible strategic partnerships or M&A

Thesis builder

Bull / base / bear

AI analysis

Bull case

Exceptional growth and profitability metrics continue to drive expansion with sustained high margins.

Base case

Maintains strong market position in generic drugs with efficient operations and pricing power.

Bear case

Elevated debt levels and potential regulatory headwinds could pressure margins and growth.

Time horizon

12-18 months

Est. CAGR

30-40%

Entry (qual.)

Current levels present attractive entry point below 220 INR

Exit (qual.)

Target price of 280-300 INR representing return to 52-week high levels

Overall conviction 75%

Knowledge graph

How it all connects

Entity graph

Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.

Portfolio impact

Does it fit your book?

Your holdings

Enter tickers + weights, then see how SPARC fits.

Enter your portfolio and hit “Analyze fit” to see SPARC's correlation, diversification benefit, and concentration impact.

Scenario simulator

Stress the thesis

Simulate a macro shock and see the illustrative impact:

Tailwind for tech & enablers.

Illustrative impact

Medium prob.

Revenue+6%

EPS+9%

Valuation+14%

Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.

Explain like…

Tailored explanations

Re-explain SPARC for a different audience:

Pick a persona to get a tailored explanation.

Important disclaimer

Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.

Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.

Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.

Position in 52-week range

Fundamentals

Executive AI briefing

What the press is saying

Who owns it

Ownership split

Top institutional holders

The numbers

Multi-year trend

Beat history

Versus peers

Price structure

What could go wrong

Moat · supply chain · M&A

What to watch next

Bull / base / bear

How it all connects

Entity graph

Does it fit your book?

Your holdings

Stress the thesis

Tailored explanations

Important disclaimer

Levels & position

Oscillators & averages